Netherlands-based Staten Biotechnology B.V. and Denmark-based Novo Nordisk A/S have entered into a collaboration agreement to co-develop Staten’s preclinical dyslipidemia candidate STT-5058 (ARGX-116). Deal terms include Staten’s ability to receive upfront fees, R&D funding, and milestone payments with $430 million Euros. Moreover, Novo Nordisk maintains the option to gain exlclusive workdwide rights to the SIMPLE antibody targeting ApoC3 and may acquire the developer.
Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemia.